Regen Biopharma Inc (RGBPP) Stock Price & Analysis
Regen Biopharma Inc (RGBPP) rose 0.22% to USD 0 as of July 25, 2026 at 05:24 UTC, according to Nexqual real-time market data.
RGBPP last closed at USD 0; the session ranged USD 0–0 on volume of 27 shares. Market capitalization is —, with a 52-week range of USD 0–0.1 (OID). Source: Nexqual, July 25, 2026 at 05:24 UTC.
Key Statistics (as of July 25, 2026 at 05:24 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.22% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.1 |
| Volume | 27 shares |
| Market Cap | — |
| Exchange | OID |
Technical Analysis (RGBPP)
Nexqual's technical model rates RGBPP "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 05:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 52.92 (neutral) |
| vs SMA50 | Above (USD 0) |
| MACD | -0 (negative) |
Analyst Ratings (RGBPP)
Wall Street analysts rate RGBPP "None", per Nexqual as of July 25, 2026 at 05:24 UTC.
| Consensus Rating | None |
|---|
Earnings (RGBPP)
Source: Nexqual, July 25, 2026 at 05:24 UTC.
Financials & Fundamentals (RGBPP)
| Total Revenue | $236,560 |
|---|---|
| Revenue Growth (YoY) | +0.00% |
| Gross Margin | +100.00% |
| Operating Margin | -260.24% |
| Profit Margin | +0.00% |
| Current Ratio | 0.05 |
| Total Cash | $271 |
| Total Debt | $959,146 |
| Free Cash Flow | $-436,287 |
Source: Nexqual, July 25, 2026 at 05:24 UTC.
Financial Health Score (RGBPP)
Nexqual rates Regen Biopharma Inc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:24 UTC.
| Growth | Mixed — Revenue +0.0% YoY (latest Q), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $271 cash, no debt |
| Cash Flow | Weak — FCF negative: -$436K, burning cash |
| Efficiency | Mixed — No data |
Ownership (RGBPP)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 158.73M |
| Float | 465.70M |
Source: Nexqual, July 25, 2026 at 05:24 UTC.
Leadership (RGBPP)
Regen Biopharma Inc is led by David Raymond Koos DBA (age 64), Chairman, CEO, President, Acting CFO, Secretary & Treasurer, per Nexqual as of July 25, 2026 at 05:24 UTC.
| Chairman, CEO, President, Acting CFO, Secretary & Treasurer | David Raymond Koos DBA (age 64) |
|---|
From Regen Biopharma Inc's Latest SEC 10-K Filing (filed 2025-12-30)
Key Strengths & Strategy (as disclosed to the SEC)
- After testing in animals, an Investigational New Drug Application ("IND") must be filed with the FDA to obtain authorization for human testing.
- No action can be taken to market any therapeutic product in the United States until an appropriate New Drug Application ("NDA") or Biologic License Application ("BLA") or has been approved by the FDA.
- The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.   DiffronC: This drug is intended to use our proprietary siRNA in vivo to inhibit cancer growth and activate T cells.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RGBP | Regen Biopharma, Inc. | USD 0 | ▲ 100% |
| GGII | Green Globe International, Inc. | USD 0 | ▲ 0% |
| HPIL | HPIL HLDG | USD 0 | ▲ 0% |
| TGGI | Trans Global Group, Inc. | USD 0 | ▲ 0% |
| KYNC | KYN Capital Group, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:24 UTC. This page is informational and not investment advice.